Semaglutide, a GLP-1 receptor agonist, signals fullness and slows digestion, while metformin improves insulin sensitivity and glucose control
Medical References Citations Branyiczky MK, Lowe MS, McMullen E, Donovan J, Khosravi-Hafshejani T
Diabetologia 41 , 271278 (1998)
Conflicting Treatments or Trials: Those currently taking other weight-loss medications or actively participating in another clinical trial are typically excluded
These medications have been shown to be beneficial in treating Type 2 diabetes, and several medications in this class have also been permitted for chronic weight management as well as cardiovascular risk reduction
Strategic caffeine use supports energy without creating dependency or disrupting sleep quality